Lepu Biopharma (HKG:2157) said it will resubmit its new drug application for nasopharyngeal cancer drug MRG003 with necessary supplementary materials to China's National Medical Products Administration on March 4, according to a Tuesday filing with the Hong Kong bourse.
MRG003 is an antibody-drug conjugate that targets EGFR on tumor cells, delivering a potent chemotherapy drug released inside the cell to trigger cancer cell death.
Previously, the NDA application was accepted by the administrator in September 2024 and was later withdrawn by the pharmaceutical company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.